U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 463

1.
Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?
Angie K. Puerto Nino, Valentina Garcia Perez, Silvia Secco, Cosimo De Nunzio, Riccardo Lombardo, Kari A. O. Tikkinen, Dean S. Elterman
Prostate Cancer Prostatic Dis. 2025; 28(1): 167–172. Published online 2024 Jun 13. doi: 10.1038/s41391-024-00847-7
PMCID:
PMC11860216
ArticlePDF–577K
2.
Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study)
Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman
Prostate Cancer Prostatic Dis. 2024; 27(3): 531–536. Published online 2024 Apr 29. doi: 10.1038/s41391-024-00833-z
PMCID:
PMC11319191
ArticlePDF–923K
3.
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Mohamed Shelan, Vérane Achard, Felix Appiagyei, Lucas Mose, Thomas Zilli, Christian D. Fankhauser, Constantinos Zamboglou, Osama Mohamad, Daniel M. Aebersold, Richard Cathomas
Prostate Cancer Prostatic Dis. 2024; 27(3): 422–431. Published online 2024 Apr 8. doi: 10.1038/s41391-024-00829-9
PMCID:
PMC11319196
ArticlePDF–637K
4.
Incidence of prostate cancer in transgender women in the US: a large database analysis
Matthew Loria, David Gilbert, Tomasz Tabernacki, Mart Andrew Maravillas, Megan McNamara, Shubham Gupta, Kirtishri Mishra
Prostate Cancer Prostatic Dis. 2025; 28(1): 232–234. Published online 2024 Feb 7. doi: 10.1038/s41391-024-00804-4
PMCID:
PMC11860230
ArticlePDF–357K
5.
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer
Kai Zhang, Phillip Stricker, Martin Löhr, Michael Stehling, Michel Suberville, Olivier Cussenot, Luca Lunelli, Chi-Fai Ng, Jeremy Teoh, Pilar Laguna, Jean de la Rosette
Prostate Cancer Prostatic Dis. 2024; 27(3): 525–530. Published online 2024 Jan 9. doi: 10.1038/s41391-023-00783-y
PMCID:
PMC11319192
ArticlePDF–576K
6.
Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer
Pamela Peeke, Sonja K. Billes, Andrew Vetter, Nader Naghavi, Diana Le, Matthew Smith, Alicia K. Morgans
Prostate Cancer Prostatic Dis. 2024; 27(4): 736–742. Published online 2023 Dec 13. doi: 10.1038/s41391-023-00771-2
PMCID:
PMC11543604
ArticlePDF–629K
7.
High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom?
Vérane Achard, Bertrand Tombal
Prostate Cancer Prostatic Dis. 2024; 27(4): 665–666. Published online 2023 Dec 8. doi: 10.1038/s41391-023-00767-y
PMCID:
PMC11543587
ArticlePDF–308K
8.
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study
Yan Hiu Athena Lee, Jeremy Man Ho Hui, Chi Ho Leung, Christopher Tze Wei Tsang, Kyle Hui, Pias Tang, Jeffrey Shi Kai Chan, Edward Christopher Dee, Kenrick Ng, Sean McBride, Paul L. Nguyen, Gary Tse, Chi Fai Ng
Prostate Cancer Prostatic Dis. 2024; 27(4): 776–782. Published online 2023 Dec 5. doi: 10.1038/s41391-023-00757-0
PMCID:
PMC11543592
ArticlePDF–1.4M
9.
Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis
Siyu Huang, Sean Ong, Dean McKenzie, Adam Mirabelli, David C. Chen, Thilakavathi Chengodu, Declan G. Murphy, Michael S. Hofman, Nathan Lawrentschuk, Marlon Perera
Prostate Cancer Prostatic Dis. 2024; 27(4): 654–664. Published online 2023 Nov 28. doi: 10.1038/s41391-023-00755-2
PMCID:
PMC11543591
ArticlePDF–1.1M
10.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
Robert Hugh Jones, Karim Fizazi, Nicholas D. James, Teuvo L. Tammela, Nobuaki Matsubara, Frank Priou, Philippe Beuzeboc, Thierry Lesimple, Petri Bono, Vesa Kataja, Jorge A. Garcia, Andrew Protheroe, Neal Shore, John Aspegren, Heikki Joensuu, Iris Kuss, Sabine Fiala-Buskies, Egils Vjaters
Prostate Cancer Prostatic Dis. 2024; 27(4): 786–789. Published online 2023 Oct 26. doi: 10.1038/s41391-023-00740-9
PMCID:
PMC11543588
ArticlePDF–360K
11.
Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study
Steve Kaplan, Ronald P. Kaufman, Jr, Thomas Mueller, Dean Elterman, Bilal Chughtai, Daniel Rukstalis, Henry Woo, Claus Roehrborn
Prostate Cancer Prostatic Dis. 2024; 27(3): 485–491. Published online 2023 Oct 26. doi: 10.1038/s41391-023-00741-8
Correction in:
Prostate Cancer Prostatic Dis. 2024; 27(3): 575.
PMCID:
PMC11319193
ArticlePDF–835K
12.
Impact of persistent PSA after salvage radical prostatectomy: a multicenter study
Felix Preisser, Reha-Baris Incesu, Pawel Rajwa, Marcin Chlosta, Florian Nohe, Mohamed Ahmed, Andre Luis Abreu, Giovanni Cacciamani, Luis Ribeiro, Alexander Kretschmer, Thilo Westhofen, Joseph A. Smith, Thomas Steuber, Giorgio Calleris, Yannic Raskin, Paolo Gontero, Steven Joniau, Rafael Sanchez-Salas, Shahrokh F. Shariat, Inderbir Gill, R. Jeffrey Karnes, Paul Cathcart, Henk Van Der Poel, Giancarlo Marra, Derya Tilki
Prostate Cancer Prostatic Dis. 2024; 27(4): 686–692. Published online 2023 Oct 6. doi: 10.1038/s41391-023-00728-5
PMCID:
PMC11543598
ArticlePDF–1.1M
13.
Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression
Stavros Gravas, Juan Manuel-Palacios, Chandrashekhar Chavan, Claus G. Roehrborn, Matthias Oelke, Marcio Augusto Averbeck, Arunangshu Biswas, Llenalia María García, Khadeeja Mohamed, Vanessa Cortes
Prostate Cancer Prostatic Dis. 2024; 27(3): 469–477. Published online 2023 Oct 4. doi: 10.1038/s41391-023-00731-w
PMCID:
PMC11319195
ArticlePDF–1.2M
14.
ANO7 African-ancestral genomic diversity and advanced prostate cancer
Jue Jiang, Pamela X. Y. Soh, Shingai B. A. Mutambirwa, M. S. Riana Bornman, Christopher A. Haiman, Vanessa M. Hayes, Weerachai Jaratlerdsiri
Prostate Cancer Prostatic Dis. 2024; 27(3): 558–565. Published online 2023 Sep 25. doi: 10.1038/s41391-023-00722-x
PMCID:
PMC11319200
ArticlePDF–1.6M
15.
Application of next-generation imaging in biochemically recurrent prostate cancer
Judd W. Moul, Neal D. Shore, Kenneth J. Pienta, Johannes Czernin, Martin T. King, Stephen J. Freedland
Prostate Cancer Prostatic Dis. 2024; 27(2): 202–211. Published online 2023 Sep 7. doi: 10.1038/s41391-023-00711-0
Correction in:
Prostate Cancer Prostatic Dis. 2024; 27(2): 358.
PMCID:
PMC11096127
ArticlePDF–687K
16.
The impact of race on survival in metastatic prostate cancer: a systematic literature review
Stephen J. Freedland, Imtiaz A. Samjoo, Emily Rosta, Austin Lansing, Evelyn Worthington, Alexander Niyazov, Jonathan Nazari, Bhakti Arondekar
Prostate Cancer Prostatic Dis. 2023; 26(3): 461–474. Published online 2023 Aug 17. doi: 10.1038/s41391-023-00710-1
PMCID:
PMC10449629
ArticlePDF–1.1M
17.
Primary bladder neck obstruction in men—new perspectives in physiopathology
Hannes Cash, Johann Jakob Wendler, Antonio Minore, Ioannis Kartalas Goumas, Luca Cindolo
Prostate Cancer Prostatic Dis. 2024; 27(1): 54–57. Published online 2023 Jul 8. doi: 10.1038/s41391-023-00691-1
PMCID:
PMC10876476
ArticlePDF–1.2M
18.
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis
Ronald Tutrone, Ben Lowentritt, Brian Neuman, Michael J. Donovan, Elliot Hallmark, T. Jeffrey Cole, Yiyuan Yao, Claire Biesecker, Sonia Kumar, Vinita Verma, Grannum R. Sant, Jason Alter, Johan Skog
Prostate Cancer Prostatic Dis. 2024; 27(1): 161. Published online 2023 Jun 19. doi: 10.1038/s41391-023-00681-3
Corrects:
Prostate Cancer Prostatic Dis. 2023; 26(3): 596–601.
PMCID:
PMC10876471
CorrectionPDF–260K
19.
Characterisation of cell lines derived from prostate cancer patients with localised disease
Leire Moya, Carina Walpole, Fiona Rae, Srilakshmi Srinivasan, Inge Seim, John Lai, David Nicol, Elizabeth D. Williams, Judith A. Clements, Jyotsna Batra
Prostate Cancer Prostatic Dis. 2023; 26(3): 614–624. Published online 2023 Jun 1. doi: 10.1038/s41391-023-00679-x
PMCID:
PMC10449630
ArticlePDF–1.9M
20.
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche, Alison L. Whitmer, Yan Yan, Bettina F. Drake, Kristen M. Sanfilippo
Prostate Cancer Prostatic Dis. 2023; 26(4): 811. Published online 2023 May 30. doi: 10.1038/s41391-023-00680-4
Corrects:
Prostate Cancer Prostatic Dis. 2023; 26(4): 743–750.
PMCID:
PMC10638080
CorrectionPDF–239K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center